ÂÜÀòÂÒÂ×

Caroline Daly has extensive work experience in the pharmaceutical industry. Caroline is currently the Senior Director of Patient Affairs EMEA at Sarepta Therapeutics since 2019. Prior to this, they held various roles at Biogen starting from 2016, including Associate Director and Senior Manager of Public Affairs Patient Advocacy.

Before Biogen, Caroline worked at Boehringer Ingelheim from 2003 to 2015. During their time there, they served as the Public Affairs/Patient Advocacy Manager in Ireland, where they developed partnerships with patient advocacy groups and influenced the implementation of patient-centric strategies. Caroline also worked as the Regional Operations Manager and Project Leader for Making More Health UK & Ireland, a long-term initiative focused on improving global health, and as a Project Manager for Exploring the Magic. Additionally, they held roles as the Regional Business Manager for North West UK and Australia at Boehringer Ingelheim, where they led teams and achieved significant sales results.

Caroline's earlier work experience includes being the Learning and Development Manager at Sanofi Synthelabo in Australia from 2001 to 2003 and a District Manager at Merck Sharp and Dohme from 1995 to 2001.

Overall, Caroline has a diverse range of experience in patient affairs, public advocacy, project management, sales, and leadership roles within the pharmaceutical industry.

Caroline Daly's education history includes a Bachelor's Degree in Registered Nursing/Registered Nurse from the University of Sydney in 1995. Caroline also pursued further education at the University of Sydney, earning a Masters in HRD and Coaching Psychology from 2002-2003. Prior to that, they studied Nurse Midwife/Nursing Midwifery at the School of Midwifery, Coombe Lying-In Hospital in Dublin, Ireland from 1988-1990. Caroline started their nursing education at Mater Hospital in Dublin, Ireland from 1985-1988. Additionally, Caroline attended St. Joseph's College in Athlone, Co. Westmeath, but no specific degree or field of study was mentioned.